CL2020003214A1 - Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 - Google Patents
Nuevos derivados de isoxazolil éter como pam de gaba a alfa5Info
- Publication number
- CL2020003214A1 CL2020003214A1 CL2020003214A CL2020003214A CL2020003214A1 CL 2020003214 A1 CL2020003214 A1 CL 2020003214A1 CL 2020003214 A CL2020003214 A CL 2020003214A CL 2020003214 A CL2020003214 A CL 2020003214A CL 2020003214 A1 CL2020003214 A1 CL 2020003214A1
- Authority
- CL
- Chile
- Prior art keywords
- alfa5
- gaba
- pam
- new derivatives
- isoxazolyl
- Prior art date
Links
- LRJJZSXDNXHKQV-UHFFFAOYSA-N 3-(1,2-oxazol-3-yloxy)-1,2-oxazole Chemical class C1=CON=C1OC=1C=CON=1 LRJJZSXDNXHKQV-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
La invención proporciona nuevos compuestos que tienen la Fórmula general (I) o (II); en donde R2, R3, R5, R99, W, Y y Z son como se describen en la presente descripción, composiciones que incluyen los compuestos y métodos de uso de los compuestos.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP18177522 | 2018-06-13 | ||
EP18177825 | 2018-06-14 |
Publications (1)
Publication Number | Publication Date |
---|---|
CL2020003214A1 true CL2020003214A1 (es) | 2021-05-07 |
Family
ID=66776367
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CL2020003214A CL2020003214A1 (es) | 2018-06-13 | 2020-12-10 | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 |
Country Status (18)
Country | Link |
---|---|
US (1) | US11840528B2 (es) |
EP (1) | EP3807269A1 (es) |
JP (1) | JP7478676B2 (es) |
KR (1) | KR20210021019A (es) |
CN (1) | CN112424196A (es) |
AU (1) | AU2019286312B2 (es) |
BR (1) | BR112020025355A2 (es) |
CA (1) | CA3102101A1 (es) |
CL (1) | CL2020003214A1 (es) |
CR (1) | CR20200610A (es) |
IL (1) | IL279266B2 (es) |
MA (1) | MA52868A (es) |
MX (1) | MX2020013518A (es) |
PE (1) | PE20210555A1 (es) |
PH (1) | PH12020500674A1 (es) |
SG (1) | SG11202012200QA (es) |
TW (1) | TWI816812B (es) |
WO (1) | WO2019238633A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202202495A (zh) | 2020-03-26 | 2022-01-16 | 匈牙利商羅特格登公司 | 作為gamma-胺基丁酸A受體次單元alpha 5受體調節劑之㖠啶及吡啶并〔3,4-c〕嗒𠯤衍生物 |
HUP2100338A1 (hu) | 2021-09-29 | 2023-04-28 | Richter Gedeon Nyrt | GABAA ALFA5 receptor modulátor hatású biciklusos aminszármazékok |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2146996A4 (en) * | 2007-04-18 | 2011-08-03 | Astrazeneca Ab | XANTHIN COMPOUNDS WITH A POSITIVE ALLOSTERIC GABAB RECEPTOR MODULATORE EFFECT |
PL2767536T3 (pl) * | 2007-12-04 | 2016-01-29 | Hoffmann La Roche | Pochodne izoksazolo-pirydyny |
US7943619B2 (en) * | 2007-12-04 | 2011-05-17 | Hoffmann-La Roche Inc. | Isoxazolo-pyridazine derivatives |
US8497278B2 (en) * | 2008-05-19 | 2013-07-30 | Sunovion Pharmaceuticals Inc. | Imidazo[1,2-a]pyridine compounds |
CA2760746C (en) | 2009-05-05 | 2017-07-11 | F. Hoffmann-La Roche Ag | Isoxazole-pyrazole derivatives |
US8604062B2 (en) | 2011-10-20 | 2013-12-10 | Hoffman-La Roche Inc. | Process for the preparation of isoxazolyl-methoxy nicotinic acids |
US8785435B2 (en) | 2011-10-20 | 2014-07-22 | Hoffmann-La Roche Inc. | Solid forms |
JP7084405B2 (ja) | 2016-12-08 | 2022-06-14 | エフ.ホフマン-ラ ロシュ アーゲー | Gaba a alpha5 pamとしての新規イソキサゾリルエーテル誘導体 |
-
2019
- 2019-06-11 WO PCT/EP2019/065129 patent/WO2019238633A1/en unknown
- 2019-06-11 EP EP19729015.8A patent/EP3807269A1/en active Pending
- 2019-06-11 SG SG11202012200QA patent/SG11202012200QA/en unknown
- 2019-06-11 PE PE2020001963A patent/PE20210555A1/es unknown
- 2019-06-11 MX MX2020013518A patent/MX2020013518A/es unknown
- 2019-06-11 CA CA3102101A patent/CA3102101A1/en active Pending
- 2019-06-11 CN CN201980046146.0A patent/CN112424196A/zh active Pending
- 2019-06-11 KR KR1020217000958A patent/KR20210021019A/ko unknown
- 2019-06-11 BR BR112020025355-3A patent/BR112020025355A2/pt unknown
- 2019-06-11 JP JP2020569188A patent/JP7478676B2/ja active Active
- 2019-06-11 MA MA052868A patent/MA52868A/fr unknown
- 2019-06-11 IL IL279266A patent/IL279266B2/en unknown
- 2019-06-11 CR CR20200610A patent/CR20200610A/es unknown
- 2019-06-11 AU AU2019286312A patent/AU2019286312B2/en active Active
- 2019-06-12 TW TW108120285A patent/TWI816812B/zh active
-
2020
- 2020-12-10 PH PH12020500674A patent/PH12020500674A1/en unknown
- 2020-12-10 CL CL2020003214A patent/CL2020003214A1/es unknown
- 2020-12-11 US US17/119,977 patent/US11840528B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
AU2019286312A1 (en) | 2021-01-07 |
WO2019238633A1 (en) | 2019-12-19 |
PE20210555A1 (es) | 2021-03-17 |
CA3102101A1 (en) | 2019-12-19 |
SG11202012200QA (en) | 2021-01-28 |
PH12020500674A1 (en) | 2021-06-07 |
KR20210021019A (ko) | 2021-02-24 |
BR112020025355A2 (pt) | 2021-03-09 |
IL279266B1 (en) | 2023-11-01 |
MX2020013518A (es) | 2021-02-26 |
CR20200610A (es) | 2021-02-05 |
JP2021527099A (ja) | 2021-10-11 |
US11840528B2 (en) | 2023-12-12 |
TWI816812B (zh) | 2023-10-01 |
EP3807269A1 (en) | 2021-04-21 |
AU2019286312B2 (en) | 2023-08-17 |
CN112424196A (zh) | 2021-02-26 |
MA52868A (fr) | 2021-04-21 |
JP7478676B2 (ja) | 2024-05-07 |
IL279266B2 (en) | 2024-03-01 |
IL279266A (en) | 2021-01-31 |
TW202016106A (zh) | 2020-05-01 |
US20210094945A1 (en) | 2021-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CO2021007056A2 (es) | Nuevos compuestos heterocíclicos | |
BR112021024224A2 (pt) | Inibidores de tead e usos dos mesmos | |
CO2019009373A2 (es) | Compuestos heterocíclicos útiles como inhibidores duales de atx/ca. | |
CO2021016015A2 (es) | Inhibidores de tead y usos de los mismos referencia cruzada a solicitudes relacionadas | |
CR20190268A (es) | Nuevos deribados de isoxazolil éter como pam de gaba a alfa5 | |
PH12021500014A1 (en) | Fused ring compounds | |
AR109393A1 (es) | Un esteroide 19-nor-c21-pirazolilo c3,3-disustituido cristalino | |
CL2020003007A1 (es) | Lactamas biciclicas y metodos de uso de las mismas (divisional solicitud no. 3486-2017) | |
CL2021001171A1 (es) | Compuestos de anillo fusionado. | |
CL2020002696A1 (es) | Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma | |
CL2017002908A1 (es) | Amidas heterocíclicas como inhibidores de quinasa. | |
CL2021000362A1 (es) | Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa | |
CR20160241A (es) | Nuevas dihidroquinolizinonas para el tratamiento y profilaxis de la infección por virus de la hepatitis b | |
CR20160419A (es) | Nuevos compuestos biciclicos | |
CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
CO2020009567A2 (es) | Inhibidores de monoacilglicerol lipasa (magl) de oxazina | |
CR20180057A (es) | Nuevos compuestos biciclicos como inhibidores duales de atx/ca. | |
CO2022002336A2 (es) | Compuestos heterocíclicos | |
CL2017002856A1 (es) | Compuestos de tioéter como inhibidores de la nitrificación | |
CL2020000101A1 (es) | Compuestos de cetonas bicíclicas y métodos de uso de los mismos. | |
CL2023000594A1 (es) | Compuestos heterocíclicos | |
CO2022008662A2 (es) | Degradadores de smarca y usos de los mismos | |
CL2022000019A1 (es) | Nuevos compuestos heterocíclicos | |
CL2020003214A1 (es) | Nuevos derivados de isoxazolil éter como pam de gaba a alfa5 | |
CL2022002661A1 (es) | Derivados de benzodiazepinas como pam de gaba a gamma1 |